Faeth Therapeutics, Inc. Variable Lease, Cost
Faeth Therapeutics, Inc. (FTH) reported Variable Lease, Cost of $439.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-04
- Faeth Therapeutics, Inc. variable lease, cost for the quarter ending 2026-06-30 was $227.00K, a 2.16% decline year-over-year.
- Faeth Therapeutics, Inc. variable lease, cost for the quarter ending 2026-03-31 was $212.00K, a 8.16% increase year-over-year.
- Faeth Therapeutics, Inc. variable lease, cost for the quarter ending 2025-12-31 was $207.00K, a 88.18% increase year-over-year.
- Faeth Therapeutics, Inc. variable lease, cost for the quarter ending 2025-09-30 was $212.00K, a 42.28% increase year-over-year.
- Faeth Therapeutics, Inc. variable lease, cost for fiscal 2025 was $847.00K, a 40.93% increase from fiscal 2024.
- Faeth Therapeutics, Inc. variable lease, cost for fiscal 2024 was $601.00K, a 10.43% decline from fiscal 2023.
- Faeth Therapeutics, Inc. variable lease, cost for fiscal 2023 was $671.00K, a 4.03% increase from fiscal 2022.
- Faeth Therapeutics, Inc. variable lease, cost for fiscal 2022 was $645.00K.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $227.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $439.00K 10-Q · filed 2026-08-04 | $646.00K derived: sum of 3 quarters · filed 2026-08-04 | $858.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $212.00K 10-Q · filed 2026-05-15 | $419.00K derived: sum of 2 quarters · filed 2026-05-15 | $631.00K derived: sum of 3 quarters · filed 2026-05-15 | $863.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $207.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $419.00K derived: sum of 2 quarters · filed 2026-03-30 | $651.00K derived: sum of 3 quarters · filed 2026-08-04 | $847.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | $212.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $444.00K derived: sum of 2 quarters · filed 2026-08-04 | $640.00K 10-Q · filed 2025-11-14 | $750.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $232.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $428.00K 10-Q · filed 2026-08-04 | $538.00K derived: sum of 3 quarters · filed 2026-08-04 | $687.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $196.00K 10-Q · filed 2026-05-15 | $306.00K derived: sum of 2 quarters · filed 2026-05-15 | $455.00K derived: sum of 3 quarters · filed 2026-05-15 | $643.00K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $110.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $259.00K derived: sum of 2 quarters · filed 2026-03-30 | $447.00K derived: sum of 3 quarters · filed 2026-03-30 | $601.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $149.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $337.00K derived: sum of 2 quarters · filed 2025-11-14 | $491.00K 10-Q · filed 2025-11-14 | $647.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $188.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $342.00K 10-Q · filed 2025-08-05 | $498.00K derived: sum of 3 quarters · filed 2025-08-05 | $633.00K derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $154.00K 10-Q · filed 2025-05-06 | $310.00K derived: sum of 2 quarters · filed 2025-05-06 | $445.00K derived: sum of 3 quarters · filed 2025-05-06 | $667.00K derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $156.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $291.00K derived: sum of 2 quarters · filed 2025-03-28 | $513.00K derived: sum of 3 quarters · filed 2025-03-28 | $671.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $135.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $357.00K derived: sum of 2 quarters · filed 2023-11-07 | $515.00K 10-Q · filed 2023-11-07 | $669.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $222.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $380.00K 10-Q · filed 2023-08-03 | $534.00K derived: sum of 3 quarters · filed 2023-08-03 | $691.00K derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | $158.00K 10-Q · filed 2023-05-09 | $312.00K derived: sum of 2 quarters · filed 2023-05-09 | $469.00K derived: sum of 3 quarters · filed 2023-05-09 | $630.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | $154.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $311.00K derived: sum of 2 quarters · filed 2023-03-29 | $472.00K derived: sum of 3 quarters · filed 2023-03-29 | $645.00K 10-K · filed 2023-03-29 |
| 2022-09-30 | $157.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $318.00K derived: sum of 2 quarters · filed 2022-11-08 | $491.00K 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $161.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $334.00K 10-Q · filed 2022-08-09 | ||
| 2022-03-31 | $173.00K 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |